Pantarhei focuses outlicensing efforts on pharmaceutical or biotech companies open to inlicense products in late stage of development. The compounds offered by Pantarhei have clear business advantages:

• Fast drug development focused on phase III
• Fast registration process due to proven safety record
• Cost effective
• Long remaining patent life

These aspects offer the licensee a potentially high return on investment.

So far the following products have been licensed out successfully:

• LH-COH in infertility to Merck-Serono
• VITS in contraception to Bayer-Schering
• DEVICE in STD diagnostics to PRD